Myelofibrosis in Evolution: Novel Standards of Care and New Challenges in Patient Management

The experts recently met in New Orleans to discuss the latest clinical data in myelofibrosis. Gain novel insights and find out how to overcome the challenges associated with diagnosis and management. Register for the OnDemand today!

OnDemand Multimedia Activity

Thank you for joining us for the myelofibrosis symposium!
Don't forget to download the activity materials to your right and apply for your CME credit!

Were you unable to attend?
The OnDemand version of the event is coming soon! Click here to be notified when it is available.

Please review the CME information for this activity prior to registering.

Why Participate?

  • Explore the biology, symptoms, and clinical burden of myelofibrosis (MF)
  • Review modern diagnostic techniques for MF, including appropriate laboratory, pathology, and mutational analyses
  • Learn how to select treatment regimens based on patient needs, symptoms burden, and risk status
  • Understand what the emergence of JAK inhibition means for clinical practice
  • Watch and listen to experts discuss challenging cases in MF, including patients presenting with serious clinical symptoms or varying degrees of risk

Important new research has transformed the care of patients with MF, one of the classic myeloproliferative neoplasms. Diagnosing and managing this rare disease however remains challenging. Patients may present with multiple symptoms and syndromes, including anemia, splenomegaly, fatigue, night sweats, and fever, among others. New diagnostic techniques, including JAK genotyping, have been developed based on important science; at the same time, updated prognostic models promise to offer a clearer picture of the risk associated with a given presentation of MF. Finally, the validation of JAK inhibition and its integration into therapeutic protocols continues to provoke questions over how to optimize treatment while addressing important safety, monitoring, and dosing issues. Join our expert panel in New Orleans and find out how these challenges can be successfully met while focusing care on the needs of the patient with MF.

Please review the CME information for this activity prior to registering.

Agenda

12:30 PM-1:00 PM:
Lunch and Registration

1:00 PM-1:10 PM:
Welcome and Introduction

1:10 PM-1:30 PM:
Myelofibrosis: Biology and Diagnosis

1:30 PM-1:50 PM:
The Clinical Burden of MF and Its Impact on Patient Health and Prognosis

1:50 PM-2:00 PM:
Ask the Faculty Q&A

2:00 PM-2:20 PM:
New Standards in MF Management: Evidence and Practical Insight

2:20 PM-2:40 PM:
The Future of MF: Meeting New Challenges in Patient Care

2:40 AM-3:00 PM:
Panel Discussion: Integrating Therapeutic Advances in MF

3:00 PM:
Final Q&A and Conclusion

Please review the CME information for this activity prior to registering.

CME Information

Activity Description & Educational Objectives

During this symposium, experts in the field of myelofibrosis (MF) will lead an interactive discussion on the latest clinical data in MF, while highlighting optimal diagnostic and management strategies for patients with this disorder. Topics to be discussed include: a new understanding of the biology of MF; recent diagnostic recommendations; the clinical burden of MF symptoms and how they affect patient health and prognosis; and the emergence of new standards of care in MF management. The panel will also address the evolution of targeted therapy in MF and profile practical issues with Janus kinase (JAK) inhibition, including dosing recommendations and appropriate follow-up strategies. Attendees will have the opportunity to ask questions and share cases for discussion with the panel.

Upon completion of this activity, participants should be better able to:

  • Implement a modern diagnostic strategy incorporating clinical assessment and advances in mutational testing for patients with suspected myelofibrosis (MF)
  • Summarize key safety and efficacy data on changing standards of care in MF and the role of JAK-STAT inhibition
  • Develop a risk-adapted management strategy for patients with MF
  • Recommend and appropriately dose novel, targeted therapies for eligible patients with MF
  • Monitor patients with MF on therapy and intervene to manage treatment-related adverse events
Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, hematologists, advanced practice oncology nurses, and other clinicians involved in the care of patients with myelofibrosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Symposium
Release and Expiration Date: Friday, December 6, 2013
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Claire Harrison, Professor (Moderator)
Consultant Haematologist & Deputy Clinical Director Cancer and Haematology
Guys' and St Thomas' Hospital
London, United Kingdom

Claire Harrison, Professor, has a financial interest/relationship or affiliation in the form of:
Consultant for Novartis Corporation; sanofi-aventis; and YM BioSciences Inc.
Grant/Research Support from Novartis Corporation.
Speakers Bureau participant with Novartis Corporation and sanofi-aventis.

Presenters

Ruben A. Mesa, MD, FACP
Consultant Hematologist
Mayo Clinic in Arizona
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Professor of Medicine
Scottsdale, Arizona

Ruben A. Mesa, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Eli Lilly and Company; Genentech, Inc.; Gilead; Incyte Corporation; and NS Pharma, Inc.

Jamile M. Shammo, MD, FASCP, FACP
Associate Professor of Medicine and Pathology
Rush University Medical Center
Chicago, Illinois

Jamile M. Shammo, MD, FASCP, FACP, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Celgene Corporation and Incyte Corporation.

Srdan Verstovsek, MD, PhD
Professor of Medicine
Chief, Section for Myeloproliferative Neoplasms (MPNs)
Department of Leukemia
Director, Clinical Research Center for MPNs
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb Company; Celgene Corporation; Geron; Gilead; Hoffmann-La Roche Inc.; Incyte Corporation; Infinity Pharmaceuticals, Inc.; Lilly Oncology; NS Pharma Inc.; Promedior, Inc.; Seattle Genetics, Inc.; and YM BioSciences Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5354-14-Z.

This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Please review the CME information for this activity prior to registering.

OnDemand Multimedia Activity

Can't participate in the live symposium?

Sign-up today to be notified when the onDemand activity becomes available online.

By registering for this activity you are attesting that you have read the CME Information for this activity.

FACULTY

Claire Harrison, Professor (Moderator)
Course Director
and Moderator

Claire Harrison, Professor (Moderator)
Guys' and St Thomas' Hospital
London, United Kingdom


Ruben A. Mesa, MD, FACP
Presenter

Ruben A. Mesa, MD, FACP
Mayo Clinic in Arizona
Mayo Clinic Cancer Center
Scottsdale, Arizona


Jamile M. Shammo, MD, FASCP, FACP
Presenter

Jamile M. Shammo, MD, FASCP, FACP
Rush University Medical Center
Chicago, Illinois


Srdan Verstovsek, MD, PhD
Presenter

Srdan Verstovsek, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas


DOWNLOADS